Plasmapheresis in combined measures to prevent postoperative thromboembolic complications in cancer patients

Plasmapheresis with exfusion of 30-60% circulating plasma volume has been first used in combination with conventional drug therapy for the prevention of postoperative thromboembolic complications in cancer patients at risk of thrombosis (II-III stage lung cancer). The use of plasmapheresis made it possible to reduce the incidence of postoperative thromboembolic complications by 40.6% and to decrease postoperative lethality.